Vorsorge des kolorektalen Karzinoms (KRK), unter besonderer Berücksichtigung der Lobbyarbeit zur Verbesserung von Information und Motivation Vorsorgeberechtigter

Zusammenfassung

Die Teilnahmerate an den gesetzlich möglichen Vorsorgemaßnahmen für das kolorektale Karzinom (KRK) liegt mit 2 % pro Jahr untere der Rate, wie sie eigentlich von den Initiatoren erwartet wurde. Diese Daten zeigen, wie wichtig Lobbyarbeit ist, um eine breite Öffentlichkeit über die Möglichkeiten der KRK-Prävention zu informieren. Die Stiftung Lebensblicke hat in diesem Sinne viel auf den Weg gebracht. Sie begleitet wissenschaftliche Untersuchungen, ist aber auch in der politischen Arbeit aktiv. Erreicht wurde dadurch, dass die bisher opportunistische Prävention zu einem Einladungsverfahren umgewandelt wird. Im zukünftigen Fokus stehen jetzt die Implementierung des immunologischen Stuhltests in der Vorsorge und die risikoadaptierte Vorsorge.

Abstract

At 2 percent, the attendance rate of advised (?) preventative initiatives for the colectoral carcinoma is well below that expected by the initiators. These data show how important lobbying is in informing the general public about the possibilities of CRC prevention. The Foundation “Lebensblicke” has done a lot in this field supporting scientific projects as well as informing policy developments. As a result, previous selective prevention will now be replaced by preventative examinations prompted by invitation. Main foci for future perspectives will be the implementation of immunological stool tests as well as risk adapted prevention.

Schlüsselwörter

Prävention - kolorektales Karzinom

Key words

Prevention - colorectal cancer

• Literatur

• 1 Damian U, Schilling D, Riemann JF. Screening auf kolorektale Karzinome. Was ist gesichert – was wird empfohlen?. Internist Prax 2013; 53: 83-90
• 2 Diamond SJ, Enestvedt BK, Jiang Z et al. Adenoma detection rate increases with each decade of life after 50 years of age. Gastroint Endosc 2011; 74: 135-140
• 3 Yuhara H, Yuhara H, Steinmaus C et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?. J Gastroenterol 2011; 106: 1911-1921
• 4 Anderson JC, Moezardalan K, Messina CR et al. Smoking and the association of advanced colorectal neoplasia in an asymptomatic average risk population: analysis of exposure and anatomical location in men and women. Dig Dis Sci 2011; 56: 3616-3623
• 5 Winawer SJ, Zauber AG, Ho MN et al. Reduction of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-1981
• 6 Schmiegel W et al. S3 Leitlinie Kolorektales Karzinom. Z Gastroenterol 2008; 46: 1-73
• 7 Tenckhoff B. KBV plädiert für gezielte Ausweitung. Deutsches Ärzteblatt 2013; 110 (15) A-703/B-617/C-617
• 8 Pox C, Altenhofen L, Brenner H et al. Efficacy of a nationwide Screening Colonoscopy program for Colorectal cancer. Gastroenterology 2012; 142: 1460-1467
• 9 RKI Krebs in Deutschland 2007/2008 online auf der RKI Homepage.
• 10 Rembacken B, Hassan C, Riemann JF et al. Quality in screening colonoscopy Position statement of the European society of Gastrointestinal Endoscopy (ESGE). Endoscopy 2012; 44: 957-968
• 11 Webendörfer S, Messerer P, Eberle F et al. Precautions for intestinal cancer in the workplace. An initiative for secondary prevention in the BASF joint-stock company. Dtsch Med Wochenschr 2004; 129 (06) 239-243
• 12 Schneider M, Häck HJ. Screening for colorectal cancer: a cost benefit analysis on a health prevention programme at the Boehringer Ingelheim Company. Dtsch Med Wochenschr 2011; 136 (20) 1047-1052
• 13 Riemann JF, Maar C, Betzler M et al. Early detection of colonic cancer in the National Cancer Program – present status and recommendations. Z Gastroenterol 2011; 49 (10) 1428-1431
• 14 Brenner H, Hoffmeister M, Arndt V et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010; 102 (02) 89-95
• 15 Brenner H, Haug U, Arndt V et al. Low risk of colorectal cancer and advanced adenomas more than 10 years after negative colonoscopy. Gastroenterology 2010; 138 (03) 870-876
• 16 Hoffmeister M, Schmitz S, Karmrodt E et al. Male sex and smoking have a larger impact on the prevalence of colorectal neoplasia than family history of colorectal cancer. Clin Gastroenterol Hepatol 2010; 8 (10) 870-876 
• 17 Brenner H, Altenhofen L, Stock C et al. Natural history of colorectal adenomas: Birth cohort analysis among 3.6 million participants of screening colonoscopy. Cancer Epidemiol Biomarkers Prev 2013 Apr 30. [Epub ahead of print]
• 18 Jorgensen OD, Kronborg O, Fenger C. A randomized study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50: 29-32
• 19 Kewenter J, Brevinge H, Engarås B et al. Results of screening, rescreening and follow-up in a prospective randomized study for detection of colorectal cancer by fecal-occult-blood testing. Scand J Gastroenterol 1994; 29: 468-473
• 20 Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for faecal occult blood. N Engl J Med 1993; 328: 1365-1371
• 21 Van Rossum LG et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90
• 22 von Karsa L, Patnick J, Segnan N. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition – Executive summary. Endoscopy 2012; 44 (Suppl 3): SE 1 – 8. Epub 2012, Sep 25
• 23 Quintero E, Castells A, Bujanda L et al. And the COLONPREV Study Investigators. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366 (08) 697-706
• 24 Knaebel HP, Kienle P. Patients at risk of familal colorectal cancer. Br Med J Med 2005; 331: 1033-1034
• 25 Blanco GD, Cretella M, Paoluzi OA et al. Adenoma, advanced adenoma and colorectal cancer prevalence in asymptomatic 40 to 49-year-olds with a first-degree family history of colorectal cancer. Colorectal Dis 2013; Apr 30. [Epub ahead of print]
• 26 Menges M, Fischinger J, Gärtner B et al. Screening colonoscopy in 40 to 50-year-old first degree relatives of patients with colorectal cancer is efficient: a controlled multicenter study. Int J Colorectal Dis 2006; 21: 301-307
• 27 Ait OuakrimD, Lockett T, Boussioutas A et al. Screening participation predictors for people at familial risk of colorectal cancer: a systematic review. Am J Prev Med 2013; 44 (05) 496-506